These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37290794)

  • 1. Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
    Hartrampf PE; Mihatsch PW; Seitz AK; Solnes LB; Rowe SP; Pomper MG; Kübler H; Bley TA; Buck AK; Werner RA
    J Nucl Med; 2023 Aug; 64(8):1272-1278. PubMed ID: 37290794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [
    Hartrampf PE; Seitz AK; Weinzierl FX; Serfling SE; Schirbel A; Rowe SP; Kübler H; Buck AK; Werner RA
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4262-4270. PubMed ID: 35650263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUV
    Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Schlötelburg W; Michalski K; Rowe SP; Pomper MG; Buck AK; Eberlein U; Werner RA
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3465-3474. PubMed ID: 37272956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of tumor markers in men with metastatic prostate cancer undergoing [
    Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
    Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.
    Wrenger R; Jüptner M; Marx M; Zhao Y; Zuhayra M; Caliebe A; Osmonov D; Lützen U
    BMC Urol; 2022 Jul; 22(1):96. PubMed ID: 35788220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.
    Widjaja L; Werner RA; Krischke E; Christiansen H; Bengel FM; Bogdanova N; Derlin T
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):602-612. PubMed ID: 36136101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Performance of RECIP 1.0 Based on [
    Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
    J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
    Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J
    J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy.
    Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE
    Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of [
    Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
    J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
    [No Abstract]   [Full Text] [Related]  

  • 15. Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
    Hartrampf PE; Weinzierl FX; Seitz AK; Kübler H; Essler M; Buck AK; Werner RA; Bundschuh RA
    Prostate; 2022 Oct; 82(14):1406-1412. PubMed ID: 35860909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-Arm, Low-Dose, Prospective Study of
    Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
    J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
    Karimzadeh A; Heck M; Tauber R; Solaris E; Nekolla S; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
    J Nucl Med; 2023 Aug; 64(8):1252-1258. PubMed ID: 37290796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
    Hartrampf PE; Bundschuh RA; Weinzierl FX; Serfling SE; Kosmala A; Seitz AK; Kübler H; Buck AK; Essler M; Werner RA
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4727-4735. PubMed ID: 35852555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Satapathy S; Sahoo RK; Bal C
    J Nucl Med; 2023 Aug; 64(8):1266-1271. PubMed ID: 37169534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.